Drug Type Fusion protein |
Synonyms AVID 200, AVID200, AVID200 DP |
Target |
Mechanism TGF-β1 inhibitors(Transforming growth factor beta 1 inhibitors), TGF-β3 inhibitors(Transforming growth factor beta 3 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mycosis Fungoides | Phase 1 | US | 15 Feb 2019 | |
Post-essential thrombocythemia myelofibrosis | Phase 1 | US | 15 Feb 2019 | |
Post-polycythemia vera myelofibrosis | Phase 1 | US | 15 Feb 2019 | |
Primary Myelofibrosis | Phase 1 | US | 15 Feb 2019 | |
Malignant Solid Neoplasm | Phase 1 | US | 07 Jan 2019 | |
Malignant Solid Neoplasm | Phase 1 | CA | 07 Jan 2019 | |
Metastatic Solid Tumor | Phase 1 | US | 07 Jan 2019 | |
Metastatic Solid Tumor | Phase 1 | CA | 07 Jan 2019 | |
Solid tumor | Phase 1 | US | 07 Jan 2019 | |
Solid tumor | Phase 1 | CA | 07 Jan 2019 |
NCT03831438 (EULAR2020) Manual | Phase 1 | - | tfnonpjcca(ewdwngfdpc) = single cases of Grade 1 dizziness and CPK elevation, and Grade 2 anemia ucmmjzvsgm (mytukbtgxd ) | Positive | 04 Jun 2020 | ||
Phase 1 | - | gzuciaoytj(vhxhbbwudc) = Grade 1 CPK elevation kvemduiiuf (kkglrovysd ) View more | - | 03 Jun 2020 | |||